Michael Taylor, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 914 S Scheuber Rd, Centralia, WA 98531 Phone: 360-736-2803 |
Lore A Monson-cox, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 914 S Scheuber Rd, Centralia, WA 98531 Phone: 360-736-2830 |
Noel Beckford, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1900 Cooks Hill Rd, Centralia, WA 98531 Phone: 800-370-4916 |
Joseph Prentice, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 914 S Scheuber Rd, Centralia, WA 98531 Phone: 360-736-2803 |
Dr. Margaret Lily Nice, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 914 S Scheuber Rd, Centralia, WA 98531 Phone: 360-736-2803 |
Mr. Barry K Wilson, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 914 S Scheuber Rd, Centralia, WA 98531 Phone: 360-736-2803 Fax: 360-330-8642 |
Chan H Lee, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 914 S Scheuber Rd, Pmg Sw Wa Centralia Anesthesiology, Centralia, WA 98531 Phone: 360-736-2803 |
News Archive
Scientists are developing a new photonics device that listens to light and could be capable of detecting skin cancer and other diseases more accurately than ever before, eliminating the need for unnecessary and invasive biopsies.
Few things are more daunting for first-time moms than the prospect of childbirth. They wonder: Will my baby be OK? What will labor and delivery be like? How painful will it be, and can I handle it? Moms who have been there offer the low-down on labor and delivery and their message is comforting.
Hybrid imaging with positron emission tomography and computed tomography (PET/CT) in the pituitary region of the brain is a promising tool for differentiating military veterans with post-traumatic stress disorder (PTSD) from those with mild traumatic brain injury (MTBI), according to a new study presented at the annual meeting of the Radiological Society of North America (RSNA).
Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA") for REOLYSIN® for the treatment of high grade gliomas (HGG) in pediatric patients.
News outlets also report that states are still conducting outreach efforts and offering the latest tallies of people who are signing up as well as information about subsidies.
› Verified 7 days ago